Trial Profile

Pharmacokinetics (PK) and Safety of Caffeine in Neonates With Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 15 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Caffeine citrate (Primary)
Indications Acute kidney injury; Brain hypoxia-ischaemia
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

08 May 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
30 Apr 2024 Planned End Date changed from 1 Jul 2026 to 1 Jul 2027.
30 Apr 2024 Planned primary completion date changed from 1 Jun 2026 to 1 Jun 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com